| 序号 | 代码 | 名称 | 估算权可 | 涨跌幅 | 成交额 | | --- | --- | --- | --- | --- | --- | | 1 | 2269 | 药明生物 | 12.83% | 1.47% | 5.49亿 | | 2 | 6160 | 百济神州 | 10.76% | -2.20% | 6.38亿 | | 3 | 1801 | 信达生物 | 9.33% | -0.34% | 6.44Z | | 4 | 1093 | 石药集团 | 7.45% | -0.99% | 6.04Z | | 5 | 9926 | 康方生物 | 7.05% | 0.58% | 3.82亿 | | 6 | 1177 | 中国生物制药 | 6.06% | -0.16% | 2.447. | | 7 | 2359 | 药明康德 | 5.23% | -0.82% | 2.95亿 | | 8 | 3692 | 翰森制药 | 4.81% | -0.23% | 1.53亿 | | ਰੇ | 1530 | 三生制药 | 3.99% | 0.63% | 2.76亿 | | 10 | 2228 | 晶泰控股 | 3.37% | - ...

证券研究报告 | 策略报告 gszqdatemark 2026 02 24 年 月 日 投资策略 年报预告景气行业的个股指引 一、策略专题：年报预告景气行业的个股指引 基于 2 月 21 日数据，我们结合业绩增长与超预期各项指标对 2025 年报 预告的景气行业进行筛选，当前景气行业主要分布于新能源、医药以及科 技三大板块，新能源景气行业包括能源金属、电池，医药景气行业包括医 疗服务、中药，科技景气行业包括元件、其他电子、游戏。本文进一步对 上述景气行业重点个股的财报进行梳理，以深化对各行业景气特征的认 知。 ——能源金属行业看，上市公司普遍提示了锂、钴等金属相关产品价格 的上涨叠加产品产量的增长，也有部分上市公司提及投资收益大幅增 长等。重点超预期个股为华友钴业。 ——电池行业看，新能源汽车及储能行业需求快速增长，电池及材料阶 段性去库存周期结束、销量大幅提升，六氟磷酸锂等材料价格迎来上 涨。重点超预期个股为璞泰来、先惠技术。 二、本周市场表现与政策事件（本周指 2 月 13 日当周） 2.1 A 股复盘：指数震荡微涨，科技股受密集催化 本周 A 股震荡微涨， 节前投资者整体保持观望情绪，市场成交量能较为低 ...

可选消费板块下跌，中国中免（601888）跌超10%。 2月24日，港股收盘走低，恒生指数跌1.82%，恒生科技指数跌2.13%。 | 香港股票 △ | | | | --- | --- | --- | | 恒生指数 | 恒生科技 | 恒生生物科技 | | 26590.32 | 5270.70 15654.19 | | | -491.59 -1.82% -114.65 -2.13% -541.42 -3.34% | | | | 港股通消费 | 港股红利 | 港股现金流 | | 1704.19 | 2318.72 | 2555.21 | | -22.73 -1.32% -2.80 -0.12% -41.84 -1.61% | | | 互联网科技股集体走低，阿里巴巴跌2.7%，金山云跌5%，快手、小米等跌逾2%。 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 ▲ | 成交额 | | --- | --- | --- | --- | --- | --- | | 0268 | 全蝶国际 | 9.970 c | -0.840 | -7.77% | 7.21亿 | | 0020 | 商沥-W | 2.610 c | - ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

Core Insights - The CRO (Contract Research Organization) industry in China is a strategic emerging industry that supports pharmaceutical innovation and is crucial for the transition from a pharmaceutical power to a pharmaceutical stronghold [1][9] - The development of policies for the CRO industry has evolved from a focus on the overall biopharmaceutical sector to specialized areas, emphasizing innovation, safety, and supply chain security [1][3] Policy Development History - The policy evolution from the "Tenth Five-Year Plan" to the "Fourteenth Five-Year Plan" has progressively recognized the importance of the CRO industry, with increasing support for specialized services [1] - The "Fifteenth Five-Year Plan" emphasizes differentiated, high-value innovation alongside supply chain security [1] National Policy Summary and Interpretation - Since 2006, multiple national policies have been introduced to support the CRO service system, focusing on regulatory standards, clinical trial optimization, and international development [3][7] - Key policies include the establishment of the MAH (Marketing Authorization Holder) system and the optimization of review and approval processes [3][7] Key National Policies (2025 Outlook) - Policies from 2006 to 2025 highlight the strategic importance of biopharmaceuticals and the CRO industry, with a focus on enhancing innovation capabilities and regulatory frameworks [4][5][6] - Recent policies aim to streamline clinical trial approvals and support the development of innovative drugs [6][10] Provincial and Municipal Policy Summary - Various provinces and cities have implemented supportive policies for the CRO industry, including investment subsidies, revenue rewards, and insurance subsidies, with some regions offering up to 50 million yuan in support [11][12] - Specific measures include allowing foreign investment in CROs and promoting AI integration in the industry [11][12][14] Provincial Development Goals - Regions like the Yangtze River Delta focus on high-end CRO service systems, while the Beijing-Tianjin-Hebei area emphasizes collaborative innovation and full-chain outsourcing [14] - Local governments aim to enhance the scale and service capabilities of the biopharmaceutical industry, with targeted initiatives for specific sectors such as seed industry CROs in Hainan [14]

公司实际控制人冯宇霞、周志文在2024年因未及时披露持股变动被监管警示，且近期有减持行为。2026 年1月，减持计划尚未结束，后续变动可能对股权结构产生影响。 经济观察网 昭衍新药（603127.SH、06127.HK）近期发布业绩预告，预计2025年归属净利润同比大增， 但营收预计下滑。公司实际控制人减持计划仍在进行，实验猴价格上涨持续影响公司利润。公司新设施 陆续投用，外部政策环境变化带来长期不确定性。 业绩经营情况 公司已于2026年1月20日发布业绩预告，预计2025年归属净利润为2.33亿元至3.49亿元，同比增幅214% 至371%，但营业收入预计同比下降13.9%至22.1%。业绩变动主要受生物资产（如实验猴）公允价值上 升驱动，而实验室服务业务利润贡献下降。投资者可关注后续正式年报的披露细节，以评估业务实际表 现。 高管变动 昭衍新药在广州的实验设施已进入竣工验收阶段，苏州设施于2025年7月通过CMA认证。新基地投产后 可能提升服务能力，但需关注订单转化效率。 政策监管 美国《生物安全法案》（纳入2026财年国防授权法案）设有五年缓冲期，短期对中国CXO企业影响有 限，但长期地缘政治风险仍需 ...

Market Performance - The overall performance of A-shares shows an increase in the earnings forecast rate, with a pre-announcement rate of 37% for 2025, up from 33.6% in 2024[5] - As of February 6, 2026, 54% of A-share companies have disclosed their earnings forecasts for 2025, compared to 51.2% in 2024[5] Sector Insights - The semiconductor and CXO sectors are expected to show strong performance, with the semiconductor equipment sector outperforming materials and components[2] - The non-bank financial sector has a pre-announcement rate exceeding 50%, with a median profit growth rate of 76.1%, while the real estate sector shows a median profit decline of 18.5%[11] Consumer Market - The overall retail sales growth for 2025 is projected at 3.7%, with service consumption growing at 5.5%, outperforming goods retail growth of 3.8%[13] - During the 2026 Spring Festival, domestic flight bookings increased by approximately 15% compared to the previous year, indicating a strong recovery in travel demand[19] Healthcare Sector - The pharmaceutical and biotech sector shows a mixed recovery, with 10% of companies expected to turn profitable, while 49% are projected to incur losses[21] - Notable companies like WuXi AppTec are expected to see a net profit increase of 102.65% in 2025, reaching 19.15 billion yuan[25] High-end Manufacturing - The engineering machinery sector is experiencing a recovery, with excavator sales in January 2026 reaching 18,708 units, a year-on-year increase of 49.5%[28] - The domestic sales of excavators increased by 61.4%, indicating strong internal demand recovery[30]

Group 1 - The Hong Kong pharmaceutical outsourcing sector experienced a strong rally on February 10, with several companies seeing significant stock price increases [1] - Zhaoyan New Drug (06127.HK), WuXi Biologics (02269.HK), and Via Biotechnology (01873.HK) all rose by over 3% [1] - Tigermed (03347.HK), WuXi AppTec (02359.HK), and Kelun Pharmaceutical (06821.HK) each saw their stock prices increase by more than 2.5% [1]

Group 1 - The Hong Kong pharmaceutical outsourcing sector has shown strong fluctuations, with companies such as Zhaoyan New Drug (06127.HK), WuXi Biologics (02269.HK), and Via Biotechnology (01873.HK) all rising over 3% [1] - Other companies like Tigermed (03347.HK), WuXi AppTec (02359.HK), and Kelun Pharmaceutical (06821.HK) have also experienced increases of more than 2.5% [1]

Core Viewpoint - The article discusses the increasing demand and rising prices for experimental monkeys in the biopharmaceutical industry, highlighting a supply shortage that is impacting drug development processes [4][5][7]. Group 1: Market Dynamics - The demand for experimental monkeys, particularly the crab-eating macaque, is critical in preclinical drug evaluations, with over 70% of large molecule drugs relying on them [8][11]. - The price of experimental monkeys has surged from approximately 80,000 yuan per monkey in early 2025 to 150,000 yuan currently, reflecting a significant supply-demand imbalance [15]. - The supply of experimental monkeys is constrained by their long breeding cycles, with a complete cycle taking 6-7 years, and each female typically producing only one offspring per year [12][17]. Group 2: Company Performance - Companies with sufficient experimental monkey resources, such as Zhaoyan New Drug, have reported significant profit increases, with net profits rising by 214% to 371% despite a revenue decline [5]. - Zhaoyan New Drug has expanded its breeding capabilities through acquisitions and self-built facilities, now housing over 10,000 monkeys, positioning itself as a leader in the market [12][17]. Group 3: Industry Trends - The biopharmaceutical industry is experiencing a shift as major Contract Research Organizations (CROs) like WuXi AppTec and Kanglong Chemical are aggressively acquiring monkey resources, which now account for over half of the industry’s total supply [17]. - A projected shortfall of approximately 10,000 experimental monkeys per year is expected in China from 2025 to 2027, indicating a growing gap between supply and demand [18]. Group 4: Regulatory and Technological Changes - Recent regulatory changes in the U.S. and China aim to reduce reliance on animal testing, promoting alternative methods such as AI and virtual models, although these technologies are not yet ready to fully replace experimental monkeys [19][20]. - The industry is encouraged to adapt to these changes by integrating traditional animal testing with emerging technologies to create a comprehensive drug development evaluation system [21].